Obesity and survival among women with ovarian cancer: Results from the Ovarian Cancer Association Consortium

British Journal of Cancer

Volumn 113, Issue 5, 2015, Pages 817-826

  Nagle, C M ^a   Dixon, S C ^a,b   Jensen, A ^c   Kjaer, S K ^c,d   Modugno, F ^e,f,g   DeFazio, A ^h,i   Fereday, S ^j   Hung, J ^h,i   Johnatty, S E ^a   Fasching, P A ^k,l   Beckmann, M W ^l   Lambrechts, D ^m,n   Vergote, I ^o   Van Nieuwenhuysen, E ^o   Lambrechts, S ^o   Risch, H A ^p   Rossing, M A ^q   Doherty, J A ^r   Wicklund, K G ^q   Chang Claude, J ^s   Goodman, M T ^t   Ness, R B ^u   Moysich, K ^v   Heitz, F ^w,x   Du Bois, A ^w,x   Harter, P ^w,x   Schwaab, I ^y   Matsuo, K ^z   Hosono, S ^aa   Goode, E L ^ab   Vierkant, R A ^ab   Larson, M C ^ab   Fridley, B L ^ac   Hogdall C ^d   Schildkraut, J M ^ad   Weber, R P ^ad   Cramer, D W ^ae   Terry, K L ^ae   Bandera, E V ^af   Paddock, L ^ag   Rodriguez Rodriguez, L ^af   Wentzensen, N ^ah   Yang, H P ^ah   Brinton, L A ^ah   Lissowska, J ^ai   Hogdall E ^c,d   Lundvall, L ^d   Whittemore, A ^aj   McGuire, V ^aj   Sieh, W ^aj   Rothstein, J ^aj   Sutphen, R ^ak   Anton Culver, H ^al   Ziogas, A ^al   Pearce, C L ^am   Wu, A H ^am   Webb, P M ^a,b   more..

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h WESTMEAD HOSPITAL   (Australia)

ⁱ WESTMEAD HOSPITAL   (Australia)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^m DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

ⁿ UNIVERSITY OF LEUVEN   (Belgium)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p YALE UNIVERSITY   (United States)

^q Fred Hutchinson Cancer Research Center   (United States)

^r DARTMOUTH MEDICAL SCHOOL   (United States)

^s GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^t CEDARS SINAI MEDICAL CENTER   (United States)

^u UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^v ROSWELL PARK CANCER INSTITUTE   (United States)

^w KLINIKEN ESSEN MITTE   (Germany)

^x DR HORST SCHMIDT KLINIKEN   (Germany)

^y Institut Für Humangenetik Wiesbaden   (Germany)

^z KYUSHU UNIVERSITY   (Japan)

^aa AICHI CANCER CENTER HOSPITAL   (Japan)

^ab MAYO CLINIC   (United States)

^ac UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^ad DUKE UNIVERSITY MEDICAL CENTER   (United States)

^ae BRIGHAM AND WOMEN S HOSPITAL   (United States)

^af ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^ag New Jersey State Cancer Registry   (United States)

^ah NATIONAL CANCER INSTITUTE   (United States)

^ai INSTITUTE OF ONCOLOGY   (Poland)

^aj STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ak UNIVERSITY OF SOUTH FLORIDA   (United States)

^al UNIVERSITY OF CALIFORNIA   (United States)

^am UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

obesity; ovarian cancer; ovarian cancer specific survival; overall survival; progression free survival

Indexed keywords

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OBESITY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR DIFFERENTIATION; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; META ANALYSIS; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY;

BODY MASS INDEX; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OBESITY; OVARIAN NEOPLASMS;

EID: 84943362588     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.245     Document Type: Article

References (66)

1. Au-Yeung G, Webb PM, Defazio A, Fereday S, Bressel M, Mileshkin L (2014) Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol 133(1): 16-22.
2. Bandera EV, King M, Chandran U, Paddock LE, Rodriguez-Rodriguez L, Olson SH (2011) Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study. BMC Womens Health 11: 40.
3. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS (2007) Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 86(3): s858-s866.
4. Bodelon C, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA (2012) Sun exposure and risk of epithelial ovarian cancer. Cancer Causes Control 23(12): 1985-1994.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17): 1625-1638.
6. Chandran U, Bandera EV, Williams-King MG, Paddock LE, Rodriguez-Rodriguez L, Lu SE, Faulkner S, Pulick K, Olson SH (2011) Healthy eating index and ovarian cancer risk. Cancer Causes Control 22(4): 563-571.
7. Chen C, Chang YC, Lan MS, Breslin M (2013) Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways. Int J Oncol 42(3): 1113-1119.
8. Clark TG, Bradburn MJ, Love SB, Altman DG (2003) Survival analysis part I: basic concepts and first analyses. Br J Cancer 89(2): 232-238.
9. Collaborative Group on Epidemiological Studies of Ovarian Cancer (2012) Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med 9(4): e1001200.
10. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3): 177-188.
11. Diaz ES, Karlan BY, Li AJ (2013) Obesity-associated adipokines correlate with survival in epithelial ovarian cancer. Gynecol Oncol 129(2): 353-357.
12. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study G (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17): 1320-1329.
13. Field KM, Kosmider S, Jefford M, Michael M, Jennens R, Green M, Gibbs P (2008) Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 4(3): 108-113.
14. Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H (1992) Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 75(6): 1497-1502.
15. Garcia-Closas M, Brinton LA, Lissowska J, Richesson D, Sherman ME, Szeszenia-Dabrowska N, Peplonska B, Welch R, Yeager M, Zatonski W, Chanock SJ (2007) Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study. BMC Cancer 7: 60.
16. Gifkins D, Olson SH, Paddock L, King M, Demissie K, Lu SE, Kong AN, Rodriguez-Rodriguez L, Bandera EV (2012) Total and individual antioxidant intake and risk of epithelial ovarian cancer. BMC Cancer 12: 211.
17. Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E, Bock JE, Blaakaer J (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164(20): 2253-2259.
18. Goode EL, Chenevix-Trench G, Hartmann LC, Fridley BL, Kalli KR, Vierkant RA, Larson MC, White KL, Keeney GL, Oberg TN, Cunningham JM, Beesley J, Johnatty SE, Chen X, Goodman KE, Armasu SM, Rider DN, Sicotte H, Schmidt MM, Elliott EA, Hogdall E, Kjaer SK, Fasching PA, Ekici AB, Lambrechts D, Despierre E, Hogdall C, Lundvall L, Karlan BY, Gross J, Brown R, Chien J, Duggan DJ, Tsai YY, Phelan CM, Kelemen LE, Peethambaram PP, Schildkraut JM, Shridhar V, Sutphen R, Couch FJ, Sellers TA. Ovarian Cancer Association C (2011) Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev 20(8): 1638-1648.
19. Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, Vierkant RA, Armasu SM, White KL, Keeney GL, Cliby WA, Rider DN, Kelemen LE, Jones MB, Peethambaram PP, Lancaster JM, Olson JE, Schildkraut JM, Cunningham JM, Hartmann LC (2010) Inherited determinants of ovarian cancer survival. Clin Cancer Res 16(3): 995-1007.
20. Goodman MT, Lurie G, Thompson PJ, McDuffie KE, Carney ME (2008) Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk. Endocr Relat Cancer 15(4): 1055-1060.
21. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. American Society of Clinical O (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 30(13): 1553-1561.
22. Hamajima N, Matsuo K, Saito T, Hirose K, Inoue M, Takezaki T, Kuroishi T, Tajima K (2001) Gene-environment Interactions and Polymorphism Studies of Cancer Risk in the Hospital-based Epidemiologic Research Program at Aichi Cancer Center II (HERPACC-II). Asian Pac J Cancer Prev 2(2): 99-107.
23. Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, Kommoss S, Heitz F, Traut A, du Bois A (2011) Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 121(3): 615-619.
24. Hogdall E, Fung ET, Christensen IJ, Yip C, Nedergaard L, Engelholm SA, Risum S, Petri AL, Lundvall L, Lomas L, Hogdall C (2010) Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Proteomics Clin Appl 4(12): 940-952.
25. Hua K, Feng W, Cao Q, Zhou X, Lu X, Feng Y (2008) Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol 33(5): 959-967.
26. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
27. Karlan BY, Jones J, Greenwald M, Lagasse LD (1995) Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am J Obstet Gynecol 173(1): 97-104.
28. Kelemen LE, Sellers TA, Schildkraut JM, Cunningham JM, Vierkant RA, Pankratz VS, Fredericksen ZS, Gadre MK, Rider DN, Liebow M, Goode EL (2008) Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. Cancer Res 68(7): 2498-2506.
29. Kelesidis I, Kelesidis T, Mantzoros CS (2006) Adiponectin and cancer: a systematic review. Br J Cancer 94(9): 1221-1225.
30. Khandekar MJ, Cohen P, Spiegelman BM (2011) Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 11(12): 886-895.
31. Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH (2011) Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121(2): 358-363.
32. Langdon SP, Hirst GL, Miller EP, Hawkins RA, Tesdale AL, Smyth JF, Miller WR (1994) The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol 50(3-4): 131-135.
33. Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB (2012) Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology 23(2): 311-319.
34. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 19(2): 237-243.
35. Makowski L, Zhou C, Zhong Y, Kuan PF, Fan C, Sampey BP, Difurio M, Bae-Jump VL (2014) Obesity increases tumor aggressiveness in a genetically engineered mouse model of serous ovarian cancer. Gynecol Oncol 133(1): 90-97.
36. McGuire V, Felberg A, Mills M, Ostrow KL, DiCioccio R, John EM, West DW, Whittemore AS (2004) Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 160(7): 613-618.
37. Merritt MA, De Pari M, Vitonis AF, Titus LJ, Cramer DW, Terry KL (2013) Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod 28(5): 1406-1417.
38. Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122(1): 170-176.
39. Modesitt SC, van Nagell Jr JR (2005) The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet Gynecol Surv 60(10): 683-692.
40. Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P, Oesterreich S (2012) Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocrine Relat Cancer 19(6): R255-R279
41. Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, Rossing MA, Terry KL, Wu AH, Risch HA, Yu H, Doherty JA, Chang-Claude J, Hein R, Nickels S, Wang-Gohrke S, Goodman MT, Carney ME, Matsuno RK, Lurie G, Moysich K, Kjaer SK, Jensen A, Hogdall E, Goode EL, Fridley BL, Vierkant RA, Larson MC, Schildkraut J, Hoyo C, Moorman P, Weber RP, Cramer DW, Vitonis AF, Bandera EV, Olson SH, Rodriguez-Rodriguez L, King M, Brinton LA, Yang H, Garcia-Closas M, Lissowska J, Anton-Culver H, Ziogas A, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Webb PM (2013) Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer 20(2): 251-262.
42. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104(12): 2807-2816.
43. Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R (2007) Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer 6(1): 113-119.
44. Parekh N, Chandran U, Bandera EV (2012) Obesity in cancer survival. Annu Rev Nutr 32: 311-342.
45. Pavelka JC, Brown RS, Karlan BY, Cass I, Leuchter RS, Lagasse LO, Li AJ (2006) Effect of obesity on survival in epithelial ovarian cancer. Cancer 107(7): 1520-1524.
46. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH (2004) Hormonal factors and the risk of invasive ovarian cancer: a populationbased case-control study. Fertil Steril 82(1): 186-195.
47. Poniewierski MS, Crawford J, Dale DC, Culakova E, Kuderer NM, Wolff DA, Lyman GH (2008) Reduced chemotherapy dose intensity in patients with ovarian cancer: Results from a prospective nationwide study. J Clin Oncol 26(Suppl): abstr 16508.
48. Protani MM, Nagle CM, Webb PM (2012) Obesity and ovarian cancer survival: a systematic review and meta-analysis. Cancer Prev Res (Phila) 5(7): 901-910.
49. Ptak A, Kolaczkowska E, Gregoraszczuk EL (2013) Leptin stimulation of cell cycle and inhibition of apoptosis gene and protein expression in OVCAR-3 ovarian cancer cells. Endocrine 43(2): 394-403.
50. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, Dicioccio RA, McGuire V, Whittemore AS, Song H, Easton DF, Pharoah PD, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Terry KL, Cramer DW, Tworoger SS, Hankinson SE, Berchuck A, Moorman PG, Schildkraut JM, Cunningham JM, Liebow M, Kjaer SK, Hogdall E, Hogdall C, Blaakaer J, Ness RB, Moysich KB, Edwards RP, Carney ME, Lurie G, Goodman MT, Wang-Gohrke S, Kropp S, Chang-Claude J, Webb PM, Chen X, Beesley J, Chenevix-Trench G, Goode EL (2008) Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer 123(2): 380-388.
51. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Million Women Study C (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335(7630): 1134.
52. Risch HA, Bale AE, Beck PA, Zheng W (2006) PGR +331A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 15(9): 1738-1741.
53. Risum S, Loft A, Hogdall C, Berthelsen AK, Hogdall E, Lundvall L, Nedergaard L, Engelholm SA (2011) Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer. Acta Oncol 50(3): 415-419.
54. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS (2007) Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 16(12): 2548-2556.
55. Royar J, Becher H, Chang-Claude J (2001) Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 95(6): 370-374.
56. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4): 343-346.
57. Schildkraut JM, Iversen ES, Wilson MA, Clyde MA, Moorman PG, Palmieri RT, Whitaker R, Bentley RC, Marks JR, Berchuck A (2010) Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One 5(4): e10061.
58. Schildkraut JM, Moorman PG, Bland AE, Halabi S, Calingaert B, Whitaker R, Lee PS, Elkins-Williams T, Bentley RC, Marks JR, Berchuck A (2008) Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev 17(3): 585-593.
59. Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Hogdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjaer SK, Jensen A, Hogdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, Garcia-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ (2013) Hormonereceptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14(9): 853-862.
60. Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, Kjaer SK (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 16(6): 1160-1166.
61. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dork T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dicks E, Doherty JA, Durst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G, Gore ME, De Vivo I, Hillemanns P, Hogdall C, Hogdall E, Iversen ES, Jacobs IJ, Jakubowska A, Li D, Lissowska J, Lubinski J, Lurie G, McGuire V, McLaughlin J, Medrek K, Moorman PG, Moysich K, Narod S, Phelan C, Pye C, Risch H, Runnebaum IB, Severi G, Southey M, Stram DO, Thiel FC, Terry KL, Tsai YY, Tworoger SS, Van Den Berg DJ, Vierkant RA, Wang-Gohrke S, Webb PM, Wilkens LR, Wu AH, Yang H, Brewster W, Ziogas A. Australian Cancer S, Australian Ovarian Cancer Study G, Ovarian Cancer Association C, Houlston R, Tomlinson I, Whittemore AS, Rossing MA, Ponder BA, Pearce CL, Ness RB, Menon U, Kjaer SK, Gronwald J, Garcia-Closas M, Fasching PA, Easton DF, Chenevix-Trench G, Berchuck A, Pharoah PD, Gayther SA (2009) A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41(9): 996-1000.
62. Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW (2005) Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 65(13): 5974-5981.
63. World Health Organisation (1995) Physical status: the use and interpretation of anthropometry. Report of a World Health Organisation Expert Committee.
64. Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC (2009) Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer 124(6): 1409-1415.
65. Zhu J, Lu X, Hua KQ, Sun H, Yu YH, Feng YJ (2012) Oestrogen receptor alpha mediates 17beta-estradiol enhancement of ovarian cancer cell motility through up-regulation of survivin expression. Arch Gynecol Obstet 286(3): 729-737.
66. Ziogas A, Gildea M, Cohen P, Bringman D, Taylor TH, Seminara D, Barker D, Casey G, Haile R, Liao SY, Thomas D, Noble B, Kurosaki T, Anton-Culver H (2000) Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 9(1): 103-111.